Biopharmas raising money in public or private financings, including: Apertura Gene Therapy, Cellectis, Cytovia, Deciphera, Dermata, Hemoglobin Oxygen, NLS, Okyo, Quantum Genomics, RVAC Medicines, Scynexis, Tempest.

Biopharmas in Asia-Pacific raising money in public or private financings: Biotech Group Acquisition, Hillevax, Oncoquest, Quest Pharmatech, Takeda.

Med-tech firms raising money in public or private financings, including: Establishment Labs.

Biopharmas raising money in public or private financings, including: Clarus, Nkarta, Sunshine, Valneva.

Cambridge Innovation Capital (CIC) has closed its oversubscribed Fund II at £225 million (US$287 million) and is moving from its previous model of open-ended investing to a traditional fixed-term venture capital fund. The money will be dedicated to spinouts from Cambridge University, with CIC investing in series A rounds, but also following on as companies mature and their capital requirements increase.

Med-tech firms raising money in public or private financings, including: Signal 1, Stentit.

Biopharmas raising money in public or private financings, including: Exogene, Forcefield, Healome, Hemostemix, Hillevax, Immunocore, Mitorx, Salarius, Savara, Scynexis, Syncona, Takeda.

Med-tech firms raising money in public or private financings, including: Bioconnection.